Abstract
Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and cognitive dysfunction seen in Parkinson's disease. The combined impact of both impairments can be assessed in gait tasks performed with concomitant cognitive tasks. The aim of this trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with established Parkinson's disease.
Original language | English |
---|---|
Pages (from-to) | 188 |
Journal | BMC Neurology |
Volume | 13 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2013 |